Indeed, previous studies showed that co‐inhibition of PYK2 and FAK enhanced the anti‐tumor efficacy of an anti‐PD‐1 immune checkpoint blockade in colorectal tumors,[23] and that PYK2, but not FAK, is required for macrophage recruitment into the TME of PTEN‐null glioblastoma multiforme (GBM) to support tumor growth. Here, PTK2B is linked to colorectal neoplasm.